An imaging probe developed at Vanderbilt detects retinal inflammation early and may allow therapeutic intervention to prevent blindness.

The discoveries that can change the course of human health forever often begin in the tiniest places: in molecules and cells, at the most fundamental intersection of physics, chemistry and biology. Understanding how these cellular and molecular processes work is the focus of basic biomedical research at Vanderbilt.

A research team led by structural biologists from Vanderbilt University has come up with the first detailed molecular explanation for a factor that may contribute to the so-called cystic fibrosis (CF) “gender gap.”

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.

Neil Osheroff, Ph.D., has been named director of the Academy for Excellence in Education. He succeeds Lillian Nanney, Ph.D., who served as director since the Academy’s inception in 2007.

Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery.

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.